(Q37598680)

English

Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Frank S Rhame

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Sandy L Rawlins

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Richard A Petruschke

3

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Tara A Erb

4

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Gregory A Winchell

5

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Helene M Wilson

6

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Jonathan M Edelman

7

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Murray A Abramson

8

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

language of work or name

0 references

publication date

1 November 2004

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

48

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

4200-4208

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

A review of low-dose ritonavir in protease inhibitor combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

Saquinavir: a review of its use in boosted regimens for treating HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

A critical evaluation of the therapeutic range of indinavir.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

Pharmacokinetic enhancement of protease inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

Principles and practice of HIV-protease inhibitor pharmacoenhancement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

Role of therapeutic drug monitoring for protease inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

Dual protease inhibitor therapy in the management of the HIV-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

23 August 2017

Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

25 June 2018

Indinavir concentrations and antiviral effect

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

25 June 2018

High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

1 September 2018

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

1 September 2018

Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

1 September 2018

Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

1 September 2018

Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

1 September 2018

Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

1 September 2018

Variability in activity of hepatic CYP3A4 in patients infected with HIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

1 September 2018

Virological response to protease inhibitor therapy in an HIV clinic cohort.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=525412

1 September 2018

Uncertain generalizability of switch studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/15504842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals

1 reference

https://pubmed.ncbi.nlm.nih.gov/15504842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.48.11.4200-4208.2004

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

release_nk4x7lh46vhopnux4rdgbq7cxm

1 reference

https://api.fatcat.wiki/v0/release/nk4x7lh46vhopnux4rdgbq7cxm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37598680&oldid=2143809405"